Advanced search
Publication Cover
Emerging Microbes & Infections Volume 11, 2022 - Issue 1
Submit an article Journal homepage
2,550
Views
4
CrossRef citations to date
0
Altmetric
Coronaviruses

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Ji-Min Seoa Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0003-2687-7495View further author information
ORCID Icon,
Bobin Kanga Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-0551-5391View further author information
ORCID Icon,
Rina Songa Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0003-3036-959XView further author information
ORCID Icon,
Hanmi Noha Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-7515-8740View further author information
ORCID Icon,
Cheolmin Kima Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-7810-5601View further author information
ORCID Icon,
Jong-In Kima Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-7376-1036View further author information
ORCID Icon,
Minsoo Kima Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0003-4394-6528View further author information
ORCID Icon,
Dong-Kyun Ryua Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0003-4237-4740View further author information
ORCID Icon,
Min-Ho Leeb New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, Republic of KoreaORCID Iconhttps://orcid.org/0000-0003-0197-3456View further author information
ORCID Icon,
Jeong-Sun Yangc Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-5005-9738View further author information
ORCID Icon,
Kyung-Chang Kimc Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-1075-0804View further author information
ORCID Icon,
Joo-Yeon Leec Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-0993-9626View further author information
ORCID Icon,
Hansaem Leec Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-9430-8123View further author information
ORCID Icon,
Hye-Min Wooc Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-8020-3489View further author information
ORCID Icon,
Jun-Won Kimc Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-9393-4248View further author information
ORCID Icon,
Jung-Ah Choid Science Unit, International Vaccine Institute, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0003-2381-7374View further author information
ORCID Icon,
Manki Songd Science Unit, International Vaccine Institute, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-8279-9041View further author information
ORCID Icon,
Monika Tomaszewska-Kiecanae Biokinetica S.A. Phase 1 Unit, Jozefow, PolandORCID Iconhttps://orcid.org/0000-0001-8501-5479View further author information
ORCID Icon,
Anna Wołowike Biokinetica S.A. Phase 1 Unit, Jozefow, PolandORCID Iconhttps://orcid.org/0000-0003-2913-948XView further author information
ORCID Icon,
Agnieszka Kuleszae Biokinetica S.A. Phase 1 Unit, Jozefow, PolandORCID Iconhttps://orcid.org/0000-0002-0006-9433View further author information
ORCID Icon,
Sunghyun Kima Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0003-3898-0393View further author information
ORCID Icon,
Keumyoung Ahna Celltrion Inc, Incheon, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-9370-5338View further author information
ORCID Icon,
Nahyun Junga Celltrion Inc, Incheon, Republic of KoreaView further author information
&
Soo-Young Leea Celltrion Inc, Incheon, Republic of KoreaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3306-9333View further author information
ORCID Icon show all
Pages 2315-2325 | Received 24 May 2022, Accepted 21 Aug 2022, Published online: 27 Sep 2022

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Eloy E. Ordaya & Raymund R. Razonable. (2024) Emerging anti-spike monoclonal antibodies against SARS-CoV-2. Expert Opinion on Biological Therapy 24:3, pages 191-201.
Read now

Articles from other publishers (3)

Qin Yalan, Hao Lingfang, Liu Xisong, Liang Run, Zhang Junjing & Zhang’ An. (2024) Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study. BMC Pharmacology and Toxicology 25:1.
Crossref
Ji Yeon Lee, Seon Hee Bu, EunHyang Song, Seongcheol Cho, Sungbong Yu, Jungok Kim, Sungmin Kym, Kwang Won Seo, Ki Tae Kwon, Jin Yong Kim, Sunghyun Kim, Keumyoung Ahn, Nahyun Jung, Yeonmi Lee, Yoobin Jung, Chankyoung Hwang & Sang Won Park. (2023) Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea. Infectious Diseases and Therapy 12:10, pages 2417-2435.
Crossref
Mahali S. Morgan, Kexin Yan, Thuy T. Le, Ryan A. Johnston, Alberto A. Amarilla, David A. Muller, Christopher L. D. McMillan, Naphak Modhiran, Daniel Watterson, James R. Potter, Julian D.J. Sng, Mary Lor, Devina Paramitha, Ariel Isaacs, Alexander A. Khromykh, Roy A. Hall, Andreas Suhrbier, Daniel J. Rawle & Jody Hobson-Peters. (2022) Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern. Viruses 15:1, pages 139.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.